NEW YORK and CLEVELAND, May 14, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity. The findings were described in a series of presentations by leading researchers, clinicians and collaborators at the Company’s annual Investor/Research & Development Day held in New York City. Members of the Athersys senior management team presented alongside distinguished panelists and provided updates on the Company’s programs including acute myocardial infarction, graft vs. host disease, ischemic stroke, inflammatory bowel disease and obesity.
